Intrinsic resistance of tumors like melanoma results from the re-activation of RTK-dependent pathways (i.e., Ras/Raf/MEK/ERK and PI3K/AKT) as consequence of treatment with their specific inhibitors [138,139,140]. This evidence concerns the gene RAF1 and melanoma.